Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial

Nathan Messas, Jean-François Tanguay, Marie Lordkipanidzé

Abstract

The recently reported ANTARCTIC trial by Cayla and colleagues is the latest large-scale study of personalized antiplatelet therapy based on platelet function testing (1). In this open-label, blinded end-point, randomized, controlled trial, the authors ascertained the net clinical benefit of individualized antiplatelet therapy based on platelet function monitoring in elderly patients undergoing stenting (PCI) for an acute coronary syndrome (ACS).